Venus Medtech (Hangzhou) (SZSC:2500) - Hisse Senedi Fiyatı, Haberler ve Analizler

2500 Stoklara Genel Bakış

Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.

Şirket hakkında

2500 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 23.4% daha düşük bir oranda işlem görüyor

Gelirin yılda 31.93% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Venus Medtech (Hangzhou) Inc. Rakipler

Acotec Scientific Holdings

SEHK:6669

HK$2.4b

Sisram Medical

SEHK:1696

HK$1.7b

MicroPort CardioFlow Medtech

SEHK:2160

HK$1.7b

Modern Dental Group

SEHK:3600

HK$3.6b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Venus Medtech (Hangzhou)
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$5.62
52 Haftanın En Yüksek Seviyesi	HK$14.94
52 Haftanın En Düşük Seviyesi	HK$3.74
Beta	0.55
11 Aylık Değişim	0%
3 Aylık Değişim	-0.71%
1 Yıllık Değişim	-61.61%
33 Yıllık Değişim	-92.66%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-92.89%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	2500	HK Medical Equipment	HK Pazar
7D	0%	-2.6%	-1.0%
1Y	-61.6%	-34.1%	15.0%

Getiri vs. Endüstri: 2500 geçen yıl % -34.1 oranında getiri sağlayan Hong Kong Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: 2500 geçen yıl % 15 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.8%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 2500 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 2500 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1,006	Lin Haosheng Lim	www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. Temel Bilgiler Özeti

Venus Medtech (Hangzhou)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2500 temel i̇stati̇sti̇kler
Piyasa değeri	HK$2.46b
Kazançlar(TTM)	-HK$1.31b
Gelir(TTM)	HK$491.35m

5.0x

P/S Oranı

-1.9x

F/K Oranı

2500 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2500 gelir tablosu (TTM)
Gelir	CN¥452.11m
Gelir Maliyeti	CN¥101.03m
Brüt Kâr	CN¥351.07m
Diğer Giderler	CN¥1.56b
Kazançlar	-CN¥1.21b

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.76
Brüt Marj	77.65%
Net Kâr Marjı	-267.18%
Borç/Özkaynak Oranı	23.4%

2500 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2500 Stoklara Genel Bakış

Ödüller

Risk Analizi

Venus Medtech (Hangzhou) Inc. Rakipler

SEHK:6669

HK$2.4b

SEHK:1696

HK$1.7b

SEHK:2160

HK$1.7b

SEHK:3600

HK$3.6b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

No longer forecast to breakeven

New minor risk - Profitability

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

No longer forecast to breakeven

Forecast breakeven date pushed back to 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Forecast to breakeven in 2022

Forecast to breakeven in 2022

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

Forecast to breakeven in 2022

GM & Executive Director recently bought HK$35m worth of stock

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

GM & Executive Director recently sold HK$304m worth of stock

Venus Medtech (Hangzhou) Inc. Announces its CEP Device, TriGUARD3, Completes its First Clinical Application in the PRC

Venus Medtech (Hangzhou) Inc. Announces Change of Joint Company Secretary

COO, CTO & Executive Director recently sold HK$280m worth of stock

COO, CTO & Executive Director recently sold HK$193m worth of stock